Teladoc Health, Inc. (NYSE:TDOC) SVP Daniel Trencher Sells 2,000 Shares

Teladoc Health, Inc. (NYSE:TDOC) SVP Daniel Trencher sold 2,000 shares of Teladoc Health stock in a transaction that occurred on Monday, May 10th. The shares were sold at an average price of $150.00, for a total transaction of $300,000.00. Following the completion of the transaction, the senior vice president now owns 25,486 shares of the company’s stock, valued at approximately $3,822,900. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Daniel Trencher also recently made the following trade(s):

  • On Monday, April 12th, Daniel Trencher sold 2,000 shares of Teladoc Health stock. The stock was sold at an average price of $181.00, for a total transaction of $362,000.00.
  • On Wednesday, February 10th, Daniel Trencher sold 3,000 shares of Teladoc Health stock. The stock was sold at an average price of $290.49, for a total transaction of $871,470.00.

NYSE TDOC opened at $145.79 on Wednesday. The company has a quick ratio of 6.47, a current ratio of 6.52 and a debt-to-equity ratio of 0.43. The company has a fifty day moving average of $177.67 and a two-hundred day moving average of $209.38. The firm has a market capitalization of $22.53 billion, a price-to-earnings ratio of -101.95 and a beta of 0.30. Teladoc Health, Inc. has a 52 week low of $133.17 and a 52 week high of $308.00.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, April 28th. The health services provider reported $0.13 earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.70. The business had revenue of $453.68 million during the quarter, compared to the consensus estimate of $452.12 million. Teladoc Health had a negative return on equity of 6.15% and a negative net margin of 12.71%. The business’s revenue for the quarter was up 150.9% compared to the same quarter last year. During the same period last year, the company earned ($0.40) earnings per share. Equities research analysts anticipate that Teladoc Health, Inc. will post -1.12 EPS for the current year.

A number of institutional investors have recently made changes to their positions in TDOC. First National Bank of South Miami boosted its position in Teladoc Health by 560.0% in the fourth quarter. First National Bank of South Miami now owns 132 shares of the health services provider’s stock valued at $26,000 after buying an additional 112 shares during the last quarter. TFO TDC LLC purchased a new stake in Teladoc Health in the 1st quarter valued at $27,000. Berman Capital Advisors LLC grew its holdings in Teladoc Health by 234.9% in the 4th quarter. Berman Capital Advisors LLC now owns 144 shares of the health services provider’s stock valued at $28,000 after buying an additional 101 shares in the last quarter. Kathmere Capital Management LLC grew its holdings in shares of Teladoc Health by 228.9% during the 4th quarter. Kathmere Capital Management LLC now owns 148 shares of the health services provider’s stock worth $30,000 after purchasing an additional 103 shares during the period. Finally, Manchester Financial Inc. grew its holdings in shares of Teladoc Health by 1,470.0% during the 4th quarter. Manchester Financial Inc. now owns 157 shares of the health services provider’s stock worth $31,000 after purchasing an additional 147 shares during the period. Institutional investors and hedge funds own 51.77% of the company’s stock.

A number of analysts have commented on TDOC shares. Truist lowered their target price on shares of Teladoc Health from $275.00 to $206.00 in a report on Monday. Craig Hallum dropped their target price on shares of Teladoc Health from $220.00 to $202.00 and set a “hold” rating on the stock in a report on Thursday, April 29th. Piper Sandler decreased their price target on shares of Teladoc Health from $305.00 to $291.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 3rd. Credit Suisse Group decreased their target price on shares of Teladoc Health from $300.00 to $264.00 and set an “outperform” rating on the stock in a research report on Thursday, May 6th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on shares of Teladoc Health from $263.00 to $226.00 and set a “buy” rating on the stock in a research report on Tuesday, March 23rd. Twelve analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $240.35.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, chronic, and complicated cases like cancer and congestive heart failure, as well as offers telehealth solutions, chronic condition management, expert medical services, behavioral health solutions, guidance and support, and platform and program services.

See Also: When can a hold rating present a buying opportunity?

Insider Buying and Selling by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.